MacroGenics, Inc.
http://www.macrogenics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MacroGenics, Inc.
FDA Perturbed By Provention's Teplizumab Type 1 Diabetes Drug
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
BMS Jumps Ahead With LAG-3 Melanoma Data
LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.
Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
US FDA’s Three Review Speeds: Standard, Priority – And Oncology
FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Raven Biotechnologies